Litigation Details for AbbVie Inc. v. Boehringer Ingelheim International GMBH (D. Del. 2017)
✉ Email this page to a colleague
AbbVie Inc. v. Boehringer Ingelheim International GMBH (D. Del. 2017)
Docket | ⤷ Sign Up | Date Filed | 2017-08-02 |
Court | District Court, D. Delaware | Date Terminated | |
Cause | 35:0145 | Assigned To | |
Jury Demand | None | Referred To | |
Patents | 9,090,867 | ||
Link to Docket | External link to docket |
Biologic Drugs cited in AbbVie Inc. v. Boehringer Ingelheim International GMBH
Details for AbbVie Inc. v. Boehringer Ingelheim International GMBH (D. Del. 2017)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2018-06-07 | 119 | Order - -Memorandum and Order | inventions claimed in any patent-in-suit shall not be so limited.” 2 U.S. Patent No. 9,090,867, titled “Fed-Batch…this nature in patent cases because it directly impacts the issues of prior art and patent validity.” BI… given the number of patents and claims at issue, and the evolution of a “patent thicket” over a lengthy… the conception of the patent. That is sure to be a large percentage of patent cases, regardless of whether… and development underlying AbbVie’s asserted patents. Boehringer’s Motion (BI Mot.) at 1 (Doc. No. | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |